Pfizer First to Seek Full Approval for Covid-19 Vaccine in U.S.

May 7, 2021, 10:45 AM

Pfizer Inc. and its partner BioNTech SE have asked U.S. regulators for full approval of their Covid-19 vaccine, a milestone in their effort to make the shot a sustainable revenue source that goes well beyond its current standing as an emergency product.

On Friday, the companies became the first Covid-19 vaccine makers to submit a biologics license application to the U.S. Food and Drug Administration. Their vaccine is one of three -- along with shots made by Moderna Inc. and Johnson & Johnson -- that hold an emergency use authorization in the U.S., a designation that can be revoked at ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.